Prostate cancer growth is often driven by male sex hormones called androgens. Hormone therapy is commonly administered to lower the level of androgens in the body, but relapse is common when the cancer cells develop resistance to these therapies. A multidisciplinary team of cancer researchers led by Angela Koehler, the Samuel A. Goldblith Career Development Professor in Applied Biology and a member of MIT’s Koch Institute for Integrative Cancer Research, has identified a small molecule that can selectively target a key protein involved in the stabilization of androgen receptor molecules….
